Mathematical modeling of tumor-induced angiogenesis

3 Early Events in Angiogenesis 6 3.1 Signaling From Tumor To Vessel at the Onset of Angiogenesis . . . . . . . . . . . . . . . . . . . . . . . . . 6 3.1.1 Transforming Growth Factor Beta (TGF) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 3.1.2 Basic Fibroblast Growth Factor (bFGF) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 3.1.3 Vascular Endothelial Growth Factor (VEGF) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 3.2 Modifications of the ECM that Facilitate EC Migration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 3.2.1 The PA-Plasmin System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 3.2.2 The MMP Family of Proteinases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9

[1]  K. Zimmermann.  Der feinere Bau der Blutcapillaren , 1923, Zeitschrift für Anatomie und Entwicklungsgeschichte.

[2]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[3]  J. Folkman,et al.  Tumor growth and neovascularization: an experimental model using the rabbit cornea. , 1974, Journal of the National Cancer Institute.

[4]  J. Folkman.  The vascularization of tumors. , 1976, Scientific American.

[5]  J. Folkman,et al.  Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. , 1977, Microvascular research.

[6]  B. Zetter,et al.  Inhibition of cell motility by interferon. , 1980, Science.

[7]  Judah Folkman,et al.  Angiogenesis in vitro , 1980, Nature.

[8]  M. Rees,et al.  Massive black hole binaries in active galactic nuclei , 1980, Nature.

[9]  R K Jain,et al.  Dynamics of neovascularization in normal tissue. , 1981, Microvascular research.

[10]  J. Folkman,et al.  Protamine is an inhibitor of angiogenesis , 1982, Nature.

[11]  R. Auerbach,et al.  Tumor-induced neovascularization in the mouse eye. , 1982, Journal of the National Cancer Institute.

[12]  G. Oster,et al.  Mechanical aspects of mesenchymal morphogenesis. , 1983, Journal of embryology and experimental morphology.

[13]  M. Sporn,et al.  Purification and initial characterization of a type beta transforming growth factor from human placenta. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Davies,et al.  Molecular Biology of the Cell , 1983, Bristol Medico-Chirurgical Journal.

[15]  G. Steele,et al.  Cancer: Principles and Practice of Oncology , 1983 .

[16]  M. Sporn,et al.  Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. , 1983, The Journal of biological chemistry.

[17]  G F Oster,et al.  A mechanical model for mesenchymal morphogenesis , 1983, Journal of mathematical biology.

[18]  Ferguson Gp,et al.  Mechanisms of neovascularization. Vascular sprouting can occur without proliferation of endothelial cells. , 1984 .

[19]  J. Wilson,et al.  Mechanisms of neovascularization. Vascular sprouting can occur without proliferation of endothelial cells. , 1984, Laboratory investigation; a journal of technical methods and pathology.

[20]  D. Lawrence,et al.  Normal embryo fibroblasts release transforming growth factors in a latent form , 1984, Journal of cellular physiology.

[21]  G. Oster,et al.  Cell traction models for generating pattern and form in morphogenesis , 1984, Journal of mathematical biology.

[22]  J. Williams,et al.  Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth. , 1985, The American journal of pathology.

[23]  D. Balding,et al.  A mathematical model of tumour-induced capillary growth. , 1985, Journal of theoretical biology.

[24]  Volcanic deposits: pyroclastic rocks. , 1985, Science.

[25]  W. Birchmeier,et al.  Transforming growth factor-beta inhibits endothelial cell proliferation. , 1986, Biochemical and biophysical research communications.

[26]  D. Rifkin,et al.  Both normal and tumor cells produce basic fibroblast growth factor , 1986, Journal of cellular physiology.

[27]  D. Lawrence,et al.  Beta-transforming growth factor is stored in human blood platelets as a latent high molecular weight complex. , 1986, Biochemical and biophysical research communications.

[28]  M. Sporn,et al.  Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[29]  P A D'Amore,et al.  Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells , 1987, The Journal of cell biology.

[30]  W. Frazier.  Thrombospondin: a modular adhesive glycoprotein of platelets and nucleated cells , 1987, The Journal of cell biology.

[31]  D. Gospodarowicz,et al.  Structural characterization and biological functions of fibroblast growth factor. , 1987, Endocrine reviews.

[32]  J. Folkman,et al.  Angiogenic factors. , 1987, Science.

[33]  D. Rifkin,et al.  Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis. , 1988, Biochimica et biophysica acta.

[34]  H. Moses,et al.  Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium , 1988, The Journal of cell biology.

[35]  D. Rifkin,et al.  Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation , 1988, The Journal of cell biology.

[36]  D. Rifkin,et al.  Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis , 1988, The Journal of cell biology.

[37]  J. Massagué,et al.  Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor-beta , 1989, The Journal of cell biology.

[38]  D. Rifkin,et al.  Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture , 1989, The Journal of cell biology.

[39]  M. Presta,et al.  The mitogenic signaling pathway but not the plasminogen activator- inducing pathway of basic fibroblast growth factor is mediated through protein kinase C in fetal bovine aortic endothelial cells , 1989, The Journal of cell biology.

[40]  N Paweletz,et al.  Tumor-related angiogenesis. , 1989, Critical reviews in oncology/hematology.

[41]  D. Rifkin,et al.  Role of extracellular matrix in the action of basic fibroblast growth factor: Matrix as a source of growth factor for long‐term stimulation of plasminogen activator production and DNA synthesis , 1989, Journal of cellular physiology.

[42]  Peter J. Polverini,et al.  Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene , 1989, Cell.

[43]  D. Rifkin,et al.  Recent developments in the cell biology of basic fibroblast growth factor , 1989, The Journal of cell biology.

[44]  D. Rifkin,et al.  Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self- regulating system , 1990, The Journal of cell biology.

[45]  R. Montesano,et al.  Proteolytic balance and capillary morphogenesis. , 1990, Cell differentiation and development : the official journal of the International Society of Developmental Biologists.

[46]  M. L. Le Beau,et al.  A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[47]  L. Orci,et al.  Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene , 1990, Cell.

[48]  C. Heldin,et al.  B-type receptor for platelet-derived growth factor mediates a chemotactic response by means of ligand-induced activation of the receptor protein-tyrosine kinase. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[49]  G. Gray,et al.  Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. , 1990, Science.

[50]  D. Rifkin,et al.  Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. , 1990 .

[51]  D. Ingber,et al.  Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth , 1990, Nature.

[52]  A. M. Turing,et al.  The chemical basis of morphogenesis , 1952, Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences.

[53]  J. Winer,et al.  The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. , 1991, Molecular endocrinology.

[54]  S. Phan,et al.  Stimulation of rat endothelial cell transforming growth factor-beta production by bleomycin. , 1991, The Journal of clinical investigation.

[55]  J. Fiddes,et al.  The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. , 1991, The Journal of biological chemistry.

[56]  D A Lauffenburger,et al.  Analysis of the roles of microvessel endothelial cell random motility and chemotaxis in angiogenesis. , 1991, Journal of theoretical biology.

[57]  J. G. Cory,et al.  Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. , 1991, Cancer communications.

[58]  A. Hudetz,et al.  Computer simulation of growth of anastomosing microvascular networks. , 1991, Journal of theoretical biology.

[59]  L. Orci,et al.  Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. , 1992, Biochemical and biophysical research communications.

[60]  Richard O. Hynes,et al.  Integrins: Versatility, modulation, and signaling in cell adhesion , 1992, Cell.

[61]  C. Streffer,et al.  The Development of the Tumour Vascular System: 2-D and 3-D Approaches to Network Formation in Human Xenografted Tumours , 1992 .

[62]  J. Winer,et al.  Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. , 1992, The Journal of biological chemistry.

[63]  D. Johnson,et al.  Structural and functional diversity in the FGF receptor multigene family. , 1993, Advances in cancer research.

[64]  J. Folkman,et al.  Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[65]  G Landini,et al.  Simulation of corneal neovascularization by inverted diffusion limited aggregation. , 1993, Investigative ophthalmology & visual science.

[66]  J. Gamble,et al.  Regulation of in vitro capillary tube formation by anti-integrin antibodies , 1993, The Journal of cell biology.

[67]  J. Martial,et al.  The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. , 1993, Endocrinology.

[68]  Y. Doki,et al.  Correlation between E-cadherin expression and invasiveness in vitro in a human esophageal cancer cell line. , 1993, Cancer research.

[69]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[70]  H. Uchiyama,et al.  Cellular adhesion molecules. , 1994, Transfusion medicine reviews.

[71]  D. Cheresh,et al.  Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels , 1994, Cell.

[72]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[73]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[74]  V. Bautch,et al.  Perturbations in the fibrinolytic pathway abolish cyst formation but not capillary-like organization of cultured murine endothelial cells. , 1994, Blood.

[75]  A. Mantovani,et al.  Tumor-associated macrophages in neoplastic progression: a paradigm for the in vivo function of chemokines. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[76]  K. Dameron,et al.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. , 1994, Science.

[77]  D. Ingber,et al.  Integrating with integrins. , 1994, Molecular biology of the cell.

[78]  T. Luther,et al.  Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. , 1994, The Journal of clinical investigation.

[79]  R. D'Amato,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[80]  J. Folkman,et al.  A strategy to discover circulating angiogenesis inhibitors generated by human tumors. , 1995, Cancer research.

[81]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[82]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[83]  S. Santoro,et al.  Loss of MDCK cell alpha 2 beta 1 integrin expression results in reduced cyst formation, failure of hepatocyte growth factor/scatter factor-induced branching morphogenesis, and increased apoptosis. , 1995, Journal of cell science.

[84]  H. M. Byrne,et al.  Mathematical models for tumour angiogenesis: Numerical simulations and nonlinear wave solutions , 1995 .

[85]  P. Bornstein,et al.  Diversity of Function Is Inherent in Matricellular Proteins: an Appraisal of Thrombospondin I , 1995 .

[86]  R J Jarvis,et al.  A mathematical analysis of a model for tumour angiogenesis , 1995, Journal of mathematical biology.

[87]  I. Lax,et al.  Regulation of growth factor activation by proteoglycans: What is the role of the low affinity receptors? , 1995, Cell.

[88]  J. Folkman,et al.  gro-beta, a -C-X-C- chemokine, is an angiogenesis inhibitor that suppresses the growth of Lewis lung carcinoma in mice , 1995, The Journal of experimental medicine.

[89]  J. Singh,et al.  A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[90]  J. Folkman.  Clinical Applications of Research on Angiogenesis , 1995 .

[91]  L. Aiello,et al.  Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[92]  R. D'Amato,et al.  Inhibition of angiogenesis in vivo by interleukin 12. , 1995, Journal of the National Cancer Institute.

[93]  Berk,et al.  Scale-invariant behavior and vascular network formation in normal and tumor tissue. , 1995, Physical review letters.

[94]  D. Cheresh,et al.  REVIEW: the integrin alpha V beta 3: angiogenesis and apoptosis. , 1995, Cell adhesion and communication.

[95]  M. Chaplain,et al.  Explicit solutions of a simplified model of capillary sprout growth during tumor angiogenesis , 1995 .

[96]  J. Rossant,et al.  Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium , 1995, Nature.

[97]  D. Taub,et al.  Human Interferon-inducible Protein 10 Is a Potent Inhibitor of Angiogenesis in Vivo , 1995 .

[98]  A. Cooper,et al.  The endothelium in psoriasis , 1995, The British journal of dermatology.

[99]  J. Duband,et al.  Control of N-cadherin-mediated intercellular adhesion in migrating neural crest cells in vitro. , 1995, Journal of cell science.

[100]  Nicola Bellomo,et al.  A Survey of Models for Tumor-Immune System Dynamics , 1996 .

[101]  N. Bouck,et al.  How tumors become angiogenic. , 1996, Advances in cancer research.

[102]  P. Polverini.  How the extracellular matrix and macrophages contribute to angiogenesis-dependent diseases. , 1996, European journal of cancer.

[103]  J. Folkman,et al.  Fighting cancer by attacking its blood supply. , 1996, Scientific American.

[104]  H M Byrne,et al.  A model of wound-healing angiogenesis in soft tissue. , 1996, Mathematical biosciences.

[105]  J. Murray,et al.  A mechanical model for the formation of vascular networks in vitro , 1996, Acta biotheoretica.

[106]  G. Davis,et al.  An alpha 2 beta 1 integrin-dependent pinocytic mechanism involving intracellular vacuole formation and coalescence regulates capillary lumen and tube formation in three-dimensional collagen matrix. , 1996, Experimental cell research.

[107]  D. Rifkin,et al.  Plasminogen activators and matrix metalloproteinases in angiogenesis. , 1996, Enzyme & protein.

[108]  A. Mantovani,et al.  Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. , 1996, Blood.

[109]  R. Jain,et al.  Role of tumor vascular architecture in nutrient and drug delivery: an invasion percolation-based network model. , 1996, Microvascular research.

[110]  S. Fox,et al.  TUMOUR ANGIOGENESIS , 1996, The Journal of pathology.

[111]  L. Orci,et al.  Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. , 1996, Enzyme & protein.

[112]  K. Hirschi,et al.  Pericytes in the microvasculature. , 1996, Cardiovascular research.

[113]  E. Ruoslahti.  How cancer spreads. , 1996, Scientific American.

[114]  P. Polverini.  Cellular adhesion molecules. Newly identified mediators of angiogenesis. , 1996, The American journal of pathology.

[115]  A. Harris,et al.  Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. , 1996, Cancer research.

[116]  R K Jain,et al.  Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[117]  M. Chaplain,et al.  A mathematical model of the first steps of tumour-related angiogenesis: capillary sprout formation and secondary branching. , 1996, IMA journal of mathematics applied in medicine and biology.

[118]  P. Lipponen.  EXPRESSION OF CATHEPSIN D IN TRANSITIONAL CELL BLADDER TUMOURS , 1996, The Journal of pathology.

[119]  D. Lauffenburger,et al.  Cell Migration: A Physically Integrated Molecular Process , 1996, Cell.

[120]  M. Chaplain,et al.  Mathematical modelling, simulation and prediction of tumour-induced angiogenesis. , 1996, Invasion & metastasis.

[121]  F Nekka,et al.  A model of growing vascular structures. , 1996, Bulletin of mathematical biology.

[122]  L. Coussens,et al.  Matrix metalloproteinases and the development of cancer. , 1996, Chemistry & biology.

[123]  Hong Li,et al.  Blockage of urokinase receptor reduces in vitro the motility and the deformability of endothelial cells , 1996, FEBS letters.

[124]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[125]  K. Wolff,et al.  Endothelial cell tube formation depends on cadherin 5 and CD31 interactions with filamentous actin. , 1997, Journal of immunology.

[126]  H. Othmer,et al.  A discrete cell model with adaptive signalling for aggregation of Dictyostelium discoideum. , 1997, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[127]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[128]  Hans G. Othmer,et al.  Aggregation, Blowup, and Collapse: The ABC's of Taxis in Reinforced Random Walks , 1997, SIAM J. Appl. Math..

[129]  K. Plate,et al.  Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system. , 1997, Cancer research.

[130]  J. Gamble,et al.  Lumen formation during angiogenesis in vitro involves phagocytic activity, formation and secretion of vacuoles, cell death, and capillary tube remodelling by different populations of endothelial cells , 1997, The Anatomical record.

[131]  B. C. Patterson,et al.  Angiostatin-converting Enzyme Activities of Human Matrilysin (MMP-7) and Gelatinase B/Type IV Collagenase (MMP-9)* , 1997, The Journal of Biological Chemistry.

[132]  W. T. Chen,et al.  Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[133]  M. Detmar,et al.  Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[134]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[135]  P. Maini,et al.  A mathematical model for the capillary endothelial cell-extracellular matrix interactions in wound-healing angiogenesis. , 1997, IMA journal of mathematics applied in medicine and biology.

[136]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. , 1997, EXS.

[137]  J. Partanen,et al.  Analysis of Tie receptor tyrosine kinase in haemopoietic progenitor and leukaemia cells , 1997, British journal of haematology.

[138]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[139]  M. O'Reilly.  Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. , 1997, EXS.

[140]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.

[141]  Z. Werb.  ECM and Cell Surface Proteolysis: Regulating Cellular Ecology , 1997, Cell.

[142]  K. Hirschi,et al.  Cell-cell interactions in vessel assembly: a model for the fundamentals of vascular remodelling. , 1997, Transplant immunology.

[143]  B. Keyt,et al.  Vascular endothelial growth factor: basic biology and clinical implications. , 1997, EXS.

[144]  K. Norrby.  Angiogenesis: new aspects relating to its initiation and control , 1997, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[145]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[146]  M. Chaplain,et al.  Two-dimensional models of tumour angiogenesis and anti-angiogenesis strategies. , 1997, IMA journal of mathematics applied in medicine and biology.

[147]  M. Dewhirst,et al.  Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. , 1997, Circulation research.

[148]  P. Hogeweg,et al.  Modelling Morphogenesis: From Single Cells to Crawling Slugs. , 1997, Journal of theoretical biology.

[149]  K. Alitalo,et al.  Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia , 1997, Oncogene.

[150]  Douglas Hanahan,et al.  Signaling Vascular Morphogenesis and Maintenance , 1997, Science.

[151]  B. Keyt,et al.  Homologous Up-regulation of KDR/Flk-1 Receptor Expression by Vascular Endothelial Growth Factor in Vitro * , 1998, The Journal of Biological Chemistry.

[152]  S. Leung,et al.  Monocyte chemoattractant protein‐1 (MCP‐1) expression in primary lymphoepithelioma‐like carcinomas (LELCs) of the lung , 1998, The Journal of pathology.

[153]  Alexander R. A. Anderson,et al.  A Mathematical Model for Capillary Network Formation in the Absence of Endothelial Cell Proliferation , 1998 .

[154]  K. Sakaguchi,et al.  Vasostatin, a Calreticulin Fragment, Inhibits Angiogenesis and Suppresses Tumor Growth , 1998, The Journal of experimental medicine.

[155]  K. Alitalo,et al.  Proinflammatory Cytokines Regulate Expression of the Lymphatic Endothelial Mitogen Vascular Endothelial Growth Factor-C* , 1998, The Journal of Biological Chemistry.

[156]  K. Plate,et al.  Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. , 1998, The American journal of pathology.

[157]  J. Folkman,et al.  Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[158]  G. Trinchieri.  Interleukin-12: a cytokine at the interface of inflammation and immunity. , 1998, Advances in immunology.

[159]  D. Grant,et al.  VE-Cadherin mediates endothelial cell capillary tube formation in fibrin and collagen gels. , 1998, Experimental cell research.

[160]  P. Rao,et al.  Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. , 1998, British Journal of Cancer.

[161]  J. Isner,et al.  Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. , 1998, Circulation research.

[162]  D. Cheresh,et al.  Disruption of Angiogenesis by PEX, a Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity , 1998, Cell.

[163]  Urban Deutsch,et al.  Angiopoietin-1 induces sprouting angiogenesis in vitro , 1998, Current Biology.

[164]  S. Mandriota,et al.  Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. , 1998, Circulation research.

[165]  K. Alitalo,et al.  Is angiopoietin-2 necessary for the initiation of tumor angiogenesis? , 1998, The American journal of pathology.

[166]  P. Koolwijk,et al.  Proteases and Angiogenesis. Regulation of Plasminogen Activators and Matrix Metalloproteases by Endothelial Cells , 1998 .

[167]  A. Iwama,et al.  Characterization of TEK receptor tyrosine kinase and its ligands, Angiopoietins, in human hematopoietic progenitor cells. , 1998, International immunology.

[168]  W. Thomas,et al.  Brain macrophages: on the role of pericytes and perivascular cells , 1999, Brain Research Reviews.

[169]  A. Ullrich,et al.  SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. , 1999, Cancer research.

[170]  William Arbuthnot Sir Lane,et al.  Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. , 1999, Science.

[171]  R. Hildenbrand,et al.  Urokinase plasminogen activator receptor (CD87) expression of tumor‐associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue , 1999, Journal of leukocyte biology.

[172]  M. Makuuchi,et al.  Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. , 1999, The Journal of clinical investigation.

[173]  V. Sukhatme,et al.  Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. , 1999, Biochemical and biophysical research communications.

[174]  M Aguet,et al.  VEGF is required for growth and survival in neonatal mice. , 1999, Development.

[175]  V. Sukhatme,et al.  Endostatin Induces Endothelial Cell Apoptosis* , 1999, The Journal of Biological Chemistry.

[176]  Alexander R. A. Anderson,et al.  A mathematical analysis of a model for capillary network formation in the absence of endothelial cell proliferation , 1999 .

[177]  C. Parent,et al.  A cell's sense of direction. , 1999, Science.

[178]  T. Veikkola,et al.  VEGFs, receptors and angiogenesis. , 1999, Seminars in cancer biology.

[179]  G. Christofori,et al.  Fibroblast Growth Factors in Tumor Progression and Angiogenesis , 1999 .

[180]  I Que,et al.  Endostatin inhibits VEGF‐induced endothelial cell migration and tumor growth independently of zinc binding , 1999, The EMBO journal.

[181]  Thomas N. Sato,et al.  Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. , 1999, Science.

[182]  W. Stetler-Stevenson,et al.  Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. , 1999, The Journal of clinical investigation.

[183]  P. Schwartzberg,et al.  Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. , 1999, Molecular cell.

[184]  E. Sage,et al.  A novel, quantitative model for study of endothelial cell migration and sprout formation within three-dimensional collagen matrices. , 1999, Microvascular research.

[185]  M. Gerritsen,et al.  Functional roles for PECAM-1 (CD31) and VE-cadherin (CD144) in tube assembly and lumen formation in three-dimensional collagen gels. , 1999, The American journal of pathology.

[186]  M. Sheetz,et al.  Cell migration as a five-step cycle. , 1999, Biochemical Society symposium.

[187]  N. Ferrara,et al.  Role of Vascular Endothelial Growth Factor in Regulation of Angiogenesis , 1999 .

[188]  H. Augustin,et al.  Induction of inflammatory angiogenesis by monocyte chemoattractant protein‐1 , 1999, International journal of cancer.

[189]  S. Ménard,et al.  Correlation between tumor vascularity, vascular endothelial growth factor production by tumor cells, serum vascular endothelial growth factor levels, and serum angiogenic activity in patients with breast carcinoma. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[190]  M. Stack,et al.  Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. , 1999, The Biochemical journal.

[191]  Hiroshi Yamamoto,et al.  Vascular endothelial growth factor acts as a pericyte mitogen under hypoxic conditions. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[192]  M. Willingham,et al.  Vitaxin, a humanized monoclonal antibody to the vitronectin receptor (alphavbeta3), reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits. , 1999, Circulation research.

[193]  D. Pode,et al.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. , 1999, The Journal of clinical investigation.

[194]  M. Chaplain,et al.  Continuous and Discrete Mathematical Models of Tumor‐Induced Angiogenesis , 1999 .

[195]  M. Chaplain,et al.  Does breast cancer exist in a state of chaos? , 1999, European journal of cancer.

[196]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[197]  K. Hirschi,et al.  Endothelial cells modulate the proliferation of mural cell precursors via platelet-derived growth factor-BB and heterotypic cell contact. , 1999, Circulation research.

[198]  Z. Han,et al.  Angiogenesis: state of the art. , 1999, International journal of hematology.

[199]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[200]  C. Wood,et al.  Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[201]  M. J. Holmes,et al.  A mathematical model of tumour angiogenesis incorporating cellular traction and viscoelastic effects. , 2000, Journal of theoretical biology.

[202]  R. Kalluri,et al.  Canstatin, a Novel Matrix-derived Inhibitor of Angiogenesis and Tumor Growth* , 2000, The Journal of Biological Chemistry.

[203]  B. Sleeman,et al.  A mathematical model for the roles of pericytes and macrophages in the initiation of angiogenesis. I. The role of protease inhibitors in preventing angiogenesis. , 2000, Mathematical biosciences.

[204]  K. W. Kim,et al.  Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. , 2000, Cancer research.

[205]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.

[206]  C Zhu,et al.  Cell mechanics: mechanical response, cell adhesion, and molecular deformation. , 2000, Annual review of biomedical engineering.

[207]  S. Kitano,et al.  Angiogenin expression in human colorectal cancer: the role of focal macrophage infiltration. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[208]  Angiogenesis inhibitors , 2000, Current oncology reports.

[209]  K. Wagner,et al.  Tie2 Receptor Expression Is Stimulated by Hypoxia and Proinflammatory Cytokines in Human Endothelial Cells , 2000, Circulation research.

[210]  T. Shearer,et al.  Involvement of cysteine proteases in bFGF-induced angiogenesis in guinea pig and rat cornea. , 2000, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[211]  R. Timpl,et al.  The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[212]  M. Detmar.  The role of VEGF and thrombospondins in skin angiogenesis. , 2000, Journal of dermatological science.

[213]  Alexander R. A. Anderson,et al.  A gradient-driven mathematical model of antiangiogenesis , 2000 .

[214]  N. Ferrara.  VEGF: an update on biological and therapeutic aspects. , 2000, Current opinion in biotechnology.

[215]  G. Breier.  Endothelial receptor tyrosine kinases involved in blood vessel development and tumor angiogenesis. , 2000, Advances in experimental medicine and biology.

[216]  Mark A. J. Chaplain,et al.  On Growth and Form: Spatio-temporal Pattern Formation in Biology , 2000 .

[217]  G. Breier,et al.  Angiogenesis in embryonic development--a review. , 2000, Placenta.

[218]  S. Philip.  Angiogenesis inhibitors in oncology. The research continues. , 2000, Cancer practice.

[219]  A. Harris,et al.  Expression of vascular endothelial growth factor by macrophages is up‐regulated in poorly vascularized areas of breast carcinomas , 2000, The Journal of pathology.

[220]  P. Maini,et al.  Development and applications of a model for cellular response to multiple chemotactic cues , 2000, Journal of mathematical biology.

[221]  G. Neufeld,et al.  The VEGF Splice Variants: Properties, Receptors, and Usage for the Treatment of Ischemic Diseases , 2000, Herz.

[222]  J. Ward,et al.  Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. , 2000, Blood.

[223]  R. Weichselbaum,et al.  Anti-angiogenic cues from vascular basement membrane collagen. , 2000, Cancer research.

[224]  R. Kalluri,et al.  Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. , 2000, The Journal of biological chemistry.

[225]  R. Kalluri,et al.  Two RGD-independent αvβ3 Integrin Binding Sites on Tumstatin Regulate Distinct Anti-tumor Properties* , 2000, The Journal of Biological Chemistry.

[226]  W. Thompson,et al.  The clinical manipulation of angiogenesis: pathology, side‐effects, surprises, and opportunities with novel human therapies , 1999, The Journal of pathology.

[227]  A. Griffioen,et al.  Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. , 2000, Pharmacological reviews.

[228]  H. Saji,et al.  Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[229]  G. Davis,et al.  RGD-Dependent Vacuolation and Lumen Formation Observed during Endothelial Cell Morphogenesis in Three-Dimensional Fibrin Matrices Involves the αvβ3 and α5β1 Integrins , 2000 .

[230]  T. Byzova,et al.  A mechanism for modulation of cellular responses to VEGF: activation of the integrins. , 2000, Molecular cell.

[231]  M. Shichiri,et al.  Antiangiogenesis signals by endostatin. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[232]  M. Schwartz,et al.  Rac recruits high-affinity integrin αvβ3 to lamellipodia in endothelial cell migration , 2001, Nature Cell Biology.

[233]  J. Lawrenson,et al.  Pericytes: Cell Biology and Pathology , 2001, Cells Tissues Organs.

[234]  B. Sleeman,et al.  Mathematical modeling of the onset of capillary formation initiating angiogenesis , 2001, Journal of mathematical biology.

[235]  K. Kaibuchi,et al.  Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. , 2001, Trends in pharmacological sciences.

[236]  J. Quigley,et al.  Growth factor-induced angiogenesis in vivo requires specific cleavage of fibrillar type I collagen. , 2001, Blood.

[237]  T. Veikkola,et al.  Interaction of endostatin with integrins implicated in angiogenesis. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[238]  L. Cantley,et al.  Endostatin regulates branching morphogenesis of renal epithelial cells and ureteric bud , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[239]  H. Yamamoto,et al.  Hypoxia down-regulates endostatin production by human microvascular endothelial cells and pericytes. , 2001, Biochemical and biophysical research communications.

[240]  M. Schwartz,et al.  Rac recruits high-affinity integrin alphavbeta3 to lamellipodia in endothelial cell migration. , 2001, Nature cell biology.

[241]  O. Volpert,et al.  Mechanistic insights on the inhibition of tumor angiogenesis , 2001, Journal of Molecular Medicine.

[242]  K. Shitara,et al.  and surface marker for the lineage of monocyte-macrophages in humans Flt-1 , vascular endothelial growth factor receptor 1 , is a novel cell , 2001 .

[243]  Richard A. Firtel,et al.  Role of Phosphatidylinositol 3′ Kinase and a Downstream Pleckstrin Homology Domain–Containing Protein in Controlling Chemotaxis inDictyostelium , 2001, The Journal of cell biology.

[244]  F. Yuan,et al.  Numerical simulations of angiogenesis in the cornea. , 2001, Microvascular research.

[245]  M. Mrksich,et al.  Direct Cell Adhesion to the Angiopoietins Mediated by Integrins* , 2001, The Journal of Biological Chemistry.

[246]  Y. Cao,et al.  Endogenous angiogenesis inhibitors and their therapeutic implications. , 2001, The international journal of biochemistry & cell biology.

[247]  T D Pollard,et al.  Regulation of actin filament network formation through ARP2/3 complex: activation by a diverse array of proteins. , 2001, Annual review of biochemistry.

[248]  B. Sleeman,et al.  Mathematical modeling of capillary formation and development in tumor angiogenesis: Penetration into the stroma , 2001, Bulletin of mathematical biology.

[249]  Po-Huang Lee,et al.  Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells. , 2001, Biochemical and biophysical research communications.

[250]  L. Ellis,et al.  Differential expression of angiopoietin‐1 and angiopoietin‐2 in colon carcinoma , 2001, Cancer.

[251]  E. De Clercq,et al.  Angiogenesis: regulators and clinical applications. , 2001, Biochemical pharmacology.

[252]  Noam Brown,et al.  The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies , 2002, The Journal of pathology.

[253]  V. Sukhatme,et al.  Endostatin Causes G1 Arrest of Endothelial Cells through Inhibition of Cyclin D1* , 2002, The Journal of Biological Chemistry.

[254]  A. Ridley,et al.  Cell migration in development and disease. , 2002, Developmental cell.

[255]  Richard A. Lang,et al.  Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[256]  Young-Guen Kwon,et al.  Endostatin binds to the catalytic domain of matrix metalloproteinase‐2 , 2002, FEBS letters.

[257]  I. Herman,et al.  Mechanisms of normal and tumor-derived angiogenesis. , 2002, American journal of physiology. Cell physiology.

[258]  古賀 一成.  Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis , 2002 .

[259]  H. Inoue,et al.  Endostatin Inhibits Adhesion of Endothelial Cells to Collagen I via α2β1 Integrin, a Possible Cause of Prevention of Chondrosarcoma Growth , 2002 .

[260]  S. McDougall,et al.  Mathematical modelling of flow through vascular networks: Implications for tumour-induced angiogenesis and chemotherapy strategies , 2002, Bulletin of mathematical biology.

[261]  H. Inoue,et al.  Endostatin inhibits adhesion of endothelial cells to collagen I via alpha(2)beta(1) integrin, a possible cause of prevention of chondrosarcoma growth. , 2002, Journal of biochemistry.

[262]  Howard A. Levine,et al.  A Mathematical Model for the Role of Cell Signal Transduction in the Initiation and Inhibition of Angiogenesis , 2003, Growth factors.

[263]  K. Norrby.  Mast cells and angiogenesis , 2002, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[264]  N. Moldovan.  Role of monocytes and macrophages in adult angiogenesis: a light at the tunnel's end. , 2002, Journal of hematotherapy & stem cell research.

[265]  J. Folkman,et al.  Angiogenesis and apoptosis. , 2003, Seminars in cancer biology.

[266]  O. Volpert,et al.  The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression , 2004, Breast Cancer Research and Treatment.

[267]  M. Toi,et al.  Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression , 2004, Breast Cancer Research and Treatment.

[268]  M. Chaplain,et al.  Mathematical Modelling of Angiogenesis , 2000, Journal of Neuro-Oncology.

[269]  J. Folkman,et al.  Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes , 2004, Angiogenesis.

[270]  S. McDougall,et al.  Mathematical modeling of tumor-induced angiogenesis. , 2006, Annual review of biomedical engineering.

[271]  T. Mak,et al.  Polarization of Chemoattractant Receptor Signaling During Neutrophil Chemotaxis , 2022 .